Skip to main content
. 2021 Feb 25;13:2009–2024. doi: 10.2147/CMAR.S296038

Figure 5.

Figure 5

Effect of MRPL13 mRNA expression on RFS of BC patients according to different clinical characteristics. Subgroup analysis of group age <50 years (A), ≥50 years (B), IDC (C), ILC (D), stage I+II (E), stage III+IV (F), Luminal (G), Her-2 overexpression (H) and TNBC (I) subtypes.